HAG
ACRS icon

HighPoint Advisor Group’s Aclaris Therapeutics ACRS Stock Holding History

HighPoint Advisor Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$587K Buy
+36,739
New +$515K 0.06% 254

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

HighPoint Advisor Group's ACRS Position: Q2 2022 in Review

HighPoint Advisor Group opened a new position in Aclaris Therapeutics (ACRS) in Q2 2022: 36,739 shares worth $587K. The stake represents 0.06% of the portfolio and ranks #254 among its holdings.

115 funds tracked by Wall St. Rank hold ACRS as of Q2 2022.

  • HighPoint Advisor Group held 36,739 shares of Aclaris Therapeutics worth $587K as of Q2 2022.
  • Aclaris Therapeutics was a new HighPoint Advisor Group position in Q2 2022.
  • Aclaris Therapeutics made up 0.06% of HighPoint Advisor Group's portfolio in Q2 2022, its #254 holding.
  • 115 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2022.

Based on HighPoint Advisor Group's 13F filing for Q2 2022, filed 15 Aug 2022.